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Today’s Merck has a much larger 
footprint and much greater responsibility 
than either Merck or Schering-Plough 
before the merger. As the integration of 
the two companies continues, we are 
reviewing our corporate responsibility 
policies, procedures and programs. 
We want to ensure that they are aligned 
to and integrated with the combined 
company’s mission and business strategy, 
while working to achieve important 
social, environmental and governance 
outcomes. We are intent on integrating 
our initiatives effectively with our day-
to-day operations and monitoring and 
reporting our progress against 
meaningful and measurable goals.
Merck remains committed to reporting 
on our performance and progress in a 
clear and straightforward way. This 
document does not provide an in-depth 
analysis of our activities and performance 
in 2009, but rather an overview of our plan 
to integrate corporate responsibility 
across all areas of the company.
Throughout this review we describe the 
actions we are taking in 2010, particularly 
as they pertain to our key areas of 
responsibility – patients and customers, 
employees and the environment. We also 
outline our ongoing commitment to operate 
in an ethical and transparent manner. 
As we focus on building a new enterprise-
wide corporate responsibility strategy, 
we will continue to use several external 
guidelines and measurement frameworks, 
including the UN Global Compact, the 
Global Reporting Initiative, the Millennium 
Development Goals and the Access to 
Medicine Index. 
The performance data in this report 
are from 2009, unless otherwise stated, 
and represent an abbreviated set of 
our previously identifi ed key performance 
indicators (KPIs). All KPIs embody 
combined, full-year data.
We intend to publish our revised goals 
by the end of 2010 and release our next 
comprehensive corporate responsibility 
report in 2011. We look forward to 
reporting the full scope of our activities 
and progress, and welcome your input 
as we shape our reporting.
IN NOVEMBER 2009, 
MERCK AND SCHERING-PLOUGH 
JOINED TOGETHER TO CREATE A NEW 
KIND OF HEALTH CARE COMPANY
Today’s Merck* is a global leader in delivering innovative health 
solutions through our medicines, vaccines, biologic therapies, 
and consumer and animal products. The combined company has 
a powerful late-stage research and development pipeline 
(www.merck.com/research/pipeline) with greater depth and 
breadth, many promising drug candidates, a signifi cantly 
broader portfolio of products and an expanded presence in key 
international markets, including high-growth emerging markets.
Our new, multi-year business strategy 
establishes our priorities as we complete 
the launch of the company, accelerate 
our growth and break through as a 
sustainable, diversifi ed, global health 
care leader. Through it, we will realize our 
mission: to provide innovative, distinctive 
products and services that save and 
improve lives and satisfy customer needs, 
to be recognized as a great place to work, 
and to provide investors with a superior 
rate of return. 
As of March 31, 2010, Merck had 
approximately 95,000 employees 
worldwide and operated in more than 
140 countries. Worldwide sales in 
2009 were $27.4 billion, an increase 
of 15 percent over 2008. Sales include 
the results of Schering-Plough 
operations from the close of the 
merger on November 3, 2009, through 
December 31, 2009.
Today’s Merck is focused on helping 
patients be well and, in doing so, our 
commitment to corporate responsibility 
has never been stronger. Our goal is to 
be a trusted partner with customers, 
public policy offi cials, suppliers and other 
important stakeholders.
We will achieve this goal by driving 
innovation in the critical areas of access to 
health and environmental sustainability, 
and by using the strength of our combined 
cultures to promote strong, ethical 
behavior and increased transparency 
in the way we do business. Through our 
actions, products and partnerships, 
we can support global health needs and 
help the world “Be Well.”
*  Merck is known as MSD outside the United States and Canada. 
2MERCK’S MISSION
To provide innovative, distinctive products and services 
that save and improve lives and satisfy customer needs, 
to be recognized as a great place to work, and to provide 
investors with a superior rate of return.
STRENGTHENING OUR APPROACH 
TO CORPORATE RESPONSIBILITY 
THROUGHOUT MERCK
1.  Assess our opportunities,
challenges and impacts
MERCK’S MISSION
2.  Design strategies for
our key priorities
3.  Defi ne goals and metrics
4.  Develop and implement policies  
and processes across company’s 
value chain for our key priorities
5. Measure and  monitor progress
6. Communicate 
progress and engage 
with stakeholders
MERCK STRATEGY MAP
OUR APPROACH TO CORPORATE RESPONSIBILITY
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BUILDING BUSINESS MOMENTUM 
OVER THE NEXT 8 YEARS
–  Unify
–  Integrate
–  Foster Culture 
–  Advance Pipeline
–  Innovate
–  Drive Effi ciencies
–  Drive Sustainable Growth  
2010–mid-2011 (Day 1–18 months) 2011–2013 (12–36 months) 2013–2018 (Years 3–8)
LAUNCH ACCELERATE BREAKTHROUGH
OUR COMMITMENTS
The principles of the UN Global Compact and the 
UN Millennium Development Goals continue to guide 
our corporate responsibility strategy.
Our commitment to the UN Global Compact 
Merck underscored its commitment to serving as a responsible global citizen in 2009 by becoming a 
signatory to the UN Global Compact. We believe that the Compact’s 10 universally accepted principles in 
the areas of human rights, labor, environment and anti-corruption are wholly aligned with our core 
mission to help the world be well. The initiative’s overarching mission to help build a more sustainable and 
inclusive global economy, and to promote global leadership through partnerships and collaboration, 
is acutely attuned to our business objectives. The principles have informed our decisions throughout our 
merger activities and inspire us as we develop our corporate responsibility strategy. 
The UN Millennium Development Goals
At Merck, we believe that, as a global community, we can all help resolve problems and aspire to 
meet the UN Millennium Development Goals (MDGs) when we fi nd ways to work together. Becoming 
a signatory to the Global Compact strengthens our commitment to contribute to the achievement 
of the MDGs, particularly those related to health care. As we set new corporate responsibility goals, 
we will continue to build on the contributions we have made to help reach the MDGs targets.
Merck will continue to support the realization of the following MDG goals:
Goal 4  Reduce Childhood Mortality
Goal 5  Improve Maternal Health
Goal 6   Combat HIV/AIDS, Malaria and Other Diseases 
Goal 8   Develop a Global Partnership for Development
4The next few years will be critical for 
global health – and for our industry. 
Health needs are becoming more severe 
and complex around the world. Access 
to quality medicines, vaccines and 
health care, business integrity, protection 
of human rights and environmental 
stewardship are but a few critical issues 
that we are called upon to address. Bold 
steps are required to accelerate progress, 
to manage risks and to seize opportunities.
Our company is well positioned for this 
new era. Our core values – our emphasis 
on scientifi c excellence and innovation, 
our focus on patient and customer 
needs, and our commitment to expand 
access to improve global health – guide 
us on this journey. 
Everything we do at Merck, every day, 
touches our customers. We have 
restructured our organization to increase 
our ability to understand, anticipate and 
meet patient and customer needs wherever 
we operate. We are making fundamental 
changes in the way we interact with our 
customers. These changes are designed 
to build strong partnerships with patients, 
payers and health care professionals 
around the world, and deliver greater 
value to them. 
We are taking steps to develop a 
comprehensive access to health strategy. 
Our vision is of a commercially sustainable 
business that increases the affordability 
and accessibility of our products globally, 
while helping build local capacity 
to provide quality health care services to 
those who need them most.
I am proud of what we have achieved and 
excited about what lies ahead: Today’s 
Merck brings together two companies 
with strong legacies of corporate 
responsibility.
This 2009–2010 Corporate Responsibility 
Review highlights our plans for Merck as 
a global health care leader – but it is only 
the beginning. To succeed, we will rely 
on our employees’ passion, creativity and 
commitment to make a difference in the 
lives of people around the world. We invite 
you to continue to engage and work 
with us on this journey toward a more 
sustainable and healthier future.
Be well, 
DICK CLARK
CHAIRMAN AND CHIEF EXECUTIVE OFFICER 
OCTOBER 2010
MESSAGE FROM THE CEO
TODAY’S MERCK TOUCHES MORE PEOPLE, INCLUDING 
MORE PATIENTS AND CUSTOMERS, MORE EMPLOYEES 
AND MORE COMMUNITIES THAN EVER BEFORE. 
Dear Friends,
We know that with greater size comes 
greater opportunity. Today’s Merck 
touches more people, including more 
patients and customers, more employees 
and more communities than ever before. 
As a result, this year we are focused 
on building the foundations that will help 
us integrate corporate responsibility 
deeper into our business and position 
us to address critical social and 
environmental challenges in a way that 
will drive shareholder value. As we work 
to develop our new strategy, we remain 
committed to the principles of the 
UN Global Compact.
Dear Stakeholders, 
Over the past decades, Merck has built 
a remarkable record as a corporate 
citizen with a focus on the well-being of 
patients worldwide. Its dedication to 
scientifi c innovation to treat and prevent 
serious diseases, including HIV/AIDS and 
other infectious diseases, heart disease 
and diabetes, and its innovative programs 
and partnerships to increase access 
to medicines not only have defi ned good 
practice but also refl ect Merck’s 
increasing emphasis on promoting and 
improving the welfare of societies. 
Two recent examples are the rotavirus 
infant vaccination program in partnership 
with the Ministry of Health in Nicaragua, 
and the efforts in Botswana to reduce 
mortality from HIV/AIDS in partnership 
with the Government of Botswana and 
the Bill & Melinda Gates Foundation.
Today, our company is working to build 
on its strength as a new global health care 
leader that combines the best practices 
and corporate responsibility legacies of 
Merck and Schering-Plough. As it does, 
it must continue to look for opportunities 
to serve unmet medical needs and 
improve access to health, while also 
providing unmatched shareholder 
value and operating with a high degree 
of transparency.
The Merck Board of Directors Committee 
on Public Policy and Social Responsibility 
has reviewed Merck’s Corporate 
Responsibility Review. On behalf of the 
Board, I am pleased to see Merck taking 
this opportunity to strengthen its 
commitment to corporate responsibility 
and expand its efforts to integrate 
responsible business practices deeper 
into the company.
The Merck Board Committee and I look 
forward to reviewing the company’s 
new corporate responsibility strategy 
later this year, and approving the 
targets and metrics that we will use to 
embed the strategy into the company’s 
day-to-day operations. 
We believe it is critical for the new 
strategy to connect with the fundamentals 
of Merck’s business and align with 
society’s expectations of a global health 
care leader – to continue to manage social 
and environmental risks, operate with 
uncompromised ethical standards, 
promote society’s well-being even in the 
most disadvantaged communities, 
and address urgent global issues, such 
as climate change and water stresses.
The combination of Merck and Schering-
Plough has created a formidable health 
care leader with vast potential for future 
discoveries and new business models that 
can provide better health care. It is an 
exciting time, but there is much important 
work that must be accomplished. While 
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MESSAGE FROM THE BOARD
TODAY, OUR COMPANY IS WORKING TO BUILD ON ITS STRENGTHS AS A NEW 
GLOBAL HEALTH CARE LEADER THAT COMBINES THE STRENGTHS AND 
CORPORATE RESPONSIBILITY LEGACIES OF MERCK AND SCHERING-PLOUGH.
continuing to forge the combined company, 
we must build and implement a new 
integrated corporate responsibility strategy 
that will enable Merck to maintain its 
leadership as a premier corporate citizen, 
while successfully growing stakeholder 
value for years to come.
We believe this is essential to the future 
sustainability of the company. 
Sincerely, 
THOMAS E. SHENK, PH.D.
CHAIR, MERCK BOARD COMMITTEE ON PUBLIC 
POLICY AND SOCIAL RESPONSIBILITY
OCTOBER 2010
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6AS PART OF OUR ONGOING DIALOGUE 
WITH STAKEHOLDERS, WE ASKED EXPERTS 
FROM A VARIETY OF DISCIPLINES 
TO COMMENT ON HOW MERCK SHOULD 
ADDRESS KEY ENVIRONMENTAL, 
SOCIAL AND GOVERNANCE ISSUES.
STAKEHOLDER VOICES
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The expectation for business in the 
21st century economy is that sustainability 
will be integrated throughout the 
corporation – from the boardroom to the 
copy room, and throughout the supply 
chain. Merck has an opportunity to lead 
its industry by developing a comprehensive 
sustainability strategy – one that 
creates accountability at the board and 
senior executive levels, incorporates 
sustainability criteria into the decision-
making process, sets aggressive 
targets and goals, and pushes for real 
performance improvements.
Mindy S. Lubber, 
President, Ceres
There is a need to reform health care 
systems across the world to manage 
coming demographic shifts that will 
pose new challenges, e.g., aging, 
population growth, etc. As one of the 
largest pharmaceutical companies, 
Merck can become the pivotal change-
maker and leader in defi ning the 
innovative cutting edge of models and 
approaches that will solve the health care 
challenges of our current and future 
times. The world currently lacks such a 
leader and Merck’s stellar past history 
facilitating the development of leading 
large-scale innovative health care 
programs aptly positions the company 
to assume this role.
Ernest Darkoh, 
 Chairman and Founding Partner, 
BroadReach Healthcare
The biggest challenge for any organization 
is to sustain performance over time. 
This holds true for businesses and 
corporate responsibility. When companies 
fi rst adopt ethical or environmental 
standards, it should be straightforward to 
show progress. For those like Merck, 
however, that cherish a particular legacy 
of social commitment, adapting to the 
demands of modern CSR is challenging 
and requires the courage of a reformer as 
well as imagination. It will therefore be 
fascinating to see the new vision that 
Merck is preparing. We must hope that – 
as Merck did in the past – the company 
will do more than catch up. It should aim 
for a big step, over the present, toward 
the next generation of values.
Robert Archer, 
Executive Director, International Council 
on Human Rights Policy
Merck has a great opportunity to 
differentiate itself through its actions 
in delivering better health care more 
creatively to everyone, especially those 
that cannot afford it. And to do this in 
a responsible way.
Susan Davis,
President & CEO, BRAC USA
 Most of Merck’s sustainability footprint 
lies outside its operations, and the 
defi nition of ‘sustainability’ increasingly 
will blend environmental, social and 
health dimensions. To create stakeholder 
value – including for shareholders – 
Merck will need to develop sustainability 
strategies spanning all three dimensions 
that minimize its negative footprint, such 
as understanding how to resolve impacts 
of compounds in water supply, and 
maximize its positive footprint, such as 
in helping adapt to health risks posed 
by climate change.
Truman Seamans, 
Principal, Green Order
“
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8HEALTH CARE REFORMS AROUND THE GLOBE 
WILL REQUIRE A GREATER FOCUS ON DELIVERING 
HIGH-QUALITY, HIGH-VALUE, HEALTH CARE 
SERVICES TO GREATER NUMBERS OF PEOPLE 
SEEKING CARE.
We are committed to improving health, not only through our signifi cantly 
expanded portfolio of medicines, vaccines, and consumer and animal health 
products, but also through far-reaching programs and partnerships. 
PATIENTS AND CUSTOMERS
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Today’s Merck is generating a renewed 
sense of urgency and focus on our 
priorities: improving the well-being of 
patients, anticipating the needs of 
our customers – including health care 
providers who treat patients – and ensuring 
the safety of our products. 
With a world of nearly 7 billion people, the 
majority living in the developing world 
where chronic disease is becoming 
increasingly prevalent, working to increase 
affordability, availability and accessibility 
to our medicines and vaccines is a key 
priority for our business. Today’s Merck is 
well suited to embrace this opportunity 
through both our research pipeline and 
our current portfolio of products that 
address a signifi cant amount of the global 
burden of disease. 
Merck is developing a global access 
to health strategy that will unify the 
policies and programs of both legacy 
companies under a common framework 
aligned with common objectives and 
commitments. In 2010, we are engaging 
stakeholders to help shape our strategy, 
and exploring opportunities to expand 
access to our products and more fully 
leverage our partnerships. 
Merck has a rich history of expanding 
access to our products through traditional 
philanthropic approaches, including 
our U.S. Patient Assistance Program, 
partnerships to support women’s health 
in least developed countries, and 
the Merck MECTIZAN® (ivermectin) 
Donation Program. 
Increasingly we see opportunity to 
address global health in a way that will 
also drive greater shareholder value. 
For example, in emerging markets we 
are developing innovative business 
models to better meet customers’ needs. 
We are also working with health care 
professionals to provide education and 
support to patients. 
In the United States where challenges 
to access for health care persist, we 
supported U.S. health care reform 
legislation that will provide health benefi ts 
to more than 32 million Americans, 
and will enhance existing coverage for 
America’s seniors. 
Reforms in the United States and 
elsewhere will require a greater focus 
on delivering high-quality, high-value, 
health care services to greater numbers 
of people seeking care. These changes 
reinforce the need for Merck to work 
closely with health care providers and 
payers in new ways that will lead to 
improved access and improved health 
outcomes. To better address these 
needs, we have adopted a new, customer-
focused approach that drives our 
decision making down to the local level, 
providing the fl exibility to understand 
and respond to provider and payer needs 
in a personalized and timely matter. 
2009 HIGHLIGHT
Product Safety
To reinforce our focus on product safety 
and ensure the well-being of patients 
worldwide, we appointed Dr. Michael 
Rosenblatt, former dean of Tufts University 
Medical School, as the company’s fi rst 
Chief Medical Offi cer in December 2009. 
Reporting directly to Richard T. Clark, 
our chairman and CEO, Dr. Rosenblatt has 
a distinguished academic and research 
career that will contribute to his unique 
and independent role as an advocate 
for patients and the global medical 
community. His expert medical input 
and informed external perspective will 
strengthen our strategies and positions 
on patient care, keeping us focused on 
the well-being of patients. 
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EXAMPLES OF HOW MERCK IS 
WORKING IN PARTNERSHIP FOR 
BETTER HEALTH 
> The Merck MECTIZAN Donation 
Program. Since 1987, Merck has provided 
MECTIZAN free of charge to treat river 
blindness through a multisectoral 
partnership that has successfully halted 
or nearly halted the disease in parts 
of Latin America and West Africa. In 1998, 
the program expanded to include 
lymphatic fi lariasis. 
> Nicaraguan Rotavirus Vaccination 
Program. In 2006, Merck, the 
Nicaraguan Ministry of Health, UNICEF 
and other leading health organizations 
established a three-year partnership to 
provide free vaccinations against 
rotavirus gastroenteritis to all eligible 
infants born in Nicaragua. Through this 
partnership – called the Nicaraguan 
Rotavirus Vaccination Program – Merck 
has provided 1.3 million free doses of 
ROTATEQ® (rotavirus vaccine, live, 
oral pentavalent) to Nicaragua, reaching 
about 90 percent of eligible children. 
Sustainability of Nicaragua’s vaccination 
program has been ensured by a 
commitment from the GAVI Alliance 
to support rotavirus vaccination and 
Merck’s access pricing policy. 
> GARDASIL® Access Program. 
Merck made a commitment to donate 
at least 3 million doses of GARDASIL® 
[Human Papillomavirus Quadrivalent 
(Types 6, 11, 16, 18) Vaccine, Recombinant] 
to organizations and institutions in 
developing countries, where more 
than 85 percent of the world’s cervical 
cancer cases occur. With the goal of 
supporting development of successful 
child and adolescent immunization models, 
the GARDASIL Access Program enables 
applicants from eligible lowest income 
countries, endorsed by their ministries of 
health, to gain operational experience in 
the design and implementation of human 
papillomavirus (HPV) vaccination projects. 
As of July 2010, more than 355,000 doses 
of GARDASIL have shipped to 13 approved 
grantees in support of their proposed 
HPV vaccination projects in 12 countries: 
Bhutan, Bolivia, Cambodia, Cameroon, 
Georgia, Haiti, Lesotho, Moldova, Nepal, 
Tanzania, Uganda and Uzbekistan. 
> MOH-MSD Partnership Program for 
Hepatitis C Eradication in Egypt. Since 
2006, Merck has been working with 
the government of Egypt to help provide 
treatment and education to Egyptians 
infected with the hepatitis C virus. More 
recently, Merck is helping the country 
achieve its goal to identify, treat and 
cure children – between the ages of 
3 to 18 – infected with the virus, through 
the program, “Virus C Free Children.” 
> Institutional Family Planning Services 
in Low and Middle Income Countries. 
For more than 25 years, Merck has 
made affordable contraceptives available
to ministries of health and non-
governmental organizations in low and 
middle income countries around the 
world. The goals of the program are to 
help decrease infant and pregnancy-
related mortality, as well as to support 
the prevention of unplanned pregnancies 
and reduce the spread of HIV/AIDS in 
regions where access to care is limited.
> African Comprehensive HIV/AIDS 
Partnerships. In 2000, the Government of 
Botswana, The Merck Company Foundation/
Merck and the Bill & Melinda Gates 
Foundation established the African 
Comprehensive HIV/AIDS Partnerships 
(ACHAP) to support and enhance 
Botswana’s response to the HIV/AIDS 
epidemic through a comprehensive 
approach to HIV/AIDS prevention, care, 
treatment and support. ACHAP has 
dramatically reduced mother-to-child 
transmission and new infections among 
children, and halved the mortality rate 
from HIV/AIDS in adults, saving more than 
50,000 lives. In 2010, Merck and The 
Gates Foundation announced continued 
support of ACHAP through 2014.
> Merck Childhood Asthma Network. This 
non-profi t organization was established in 
2005 to address the complex and growing 
problem of pediatric asthma in the 
United States by advancing evidence-
based programs that improve the quality 
of life for children with asthma, and to 
reduce, through dissemination of effective 
interventions, the burden of the disease 
on them and society. 
> Afya Serengeti Project in Tanzania. 
Since 2003, Intervet/Schering-Plough 
Animal Health has been donating doses 
of the rabies vaccine to control rabies 
around the Serengeti Reservation in 
Tanzania. Since the start of the program 
in 2003, more than 1 million doses of 
the vaccine have been donated, and the 
number of people requiring hospital care 
for bites from rabid dogs has dropped 
82 percent.
11 2009–2010 CORPORATE RESPONSIBILITY REVIEW
MSD Wellcome Trust 
Hilleman Laboratories
In 2009, Merck joined with the Wellcome 
Trust to establish the MSD Wellcome Trust 
Hilleman Laboratories, a research and 
development organization that intends 
to develop affordable vaccines for 
millions of people in some of the poorest 
areas of the world. Many scientists 
identify vaccine candidates potentially 
useful to developing countries, but 
face signifi cant challenges in product 
development and formulations because 
they lack the resources typically 
available only within large vaccine 
companies. Based in India, the Hilleman 
Laboratories is leveraging Merck’s 
expertise in vaccine development 
and the Wellcome Trust’s excellence 
in global biomedical research in a 
sustainable not-for-profi t model that has 
the potential to revolutionize the way we 
address pressing health challenges in the 
developing world. Merck was honored 
to receive the Vaccine Industry Excellence 
Award for the Best Vaccine Partnership/
Alliance/License in 2010 for this innovative 
collaboration.
2009–2010 HIGHLIGHTS
HUMAN HEALTH GEOGRAPHIC SALES (as of 1Q10)FRANCHISE/KEY PRODUCT BY SALES (as of 1Q10)
Europe, Middle East and Asia 33%
Rest of World 17%
Japan 8%
U.S. 42%
Global Human Health Sales 86%
Animal Health Sales 6%
Other Revenues 5%
Consumer Care Sales 3%
MerckEngage
MerckEngage.com, a free online tool 
available in the U.S., offers resources 
that reinforce healthy lifestyle changes, 
provide disease-specifi c education, 
support adherence to therapy and help 
U.S. health care consumers have more 
productive interactions with their health 
care professionals. This assistance is 
augmented with critical support and 
encouragement for caregivers, who are 
often engaged in the day-to-day care 
and treatment decisions of family 
members and friends. The Internet site, 
launched in February 2010, is one 
component of the new MerckEngage 
Health Partnership Program that 
provides health care professionals with 
health support materials and tools for 
their patients who have been prescribed 
certain Merck medications. The Program 
is designed to support the health care 
professional/health care consumer 
relationship by providing tools and tips for 
healthier living and encouraging health 
care consumers to make healthier 
lifestyle choices between office visits, 
through a variety of resources offered 
online, in print and through a call center. 
A unique aspect of the MerckEngage 
Health Partnership Program is the 
availability of health coaches who provide 
one-on-one coaching with eligible 
members to help them achieve their own 
health goals. 
Access to Medicines
In 2010, the Access to Medicine Index, 
which ranks pharmaceutical companies 
on various criteria around global access 
to medicines, ranked Merck No. 2 among 
the top 20 pharmaceutical companies.
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EMPLOYEES
AS A LARGER COMPANY WITH A BROADER REACH 
AND GREATER RESPONSIBILITY, WE BELIEVE THAT 
THE SUCCESSFUL INTEGRATION OF OUR PEOPLE 
IS CRITICAL TO THE SUCCESS OF OUR BUSINESS. 
To achieve our business goals, we rely on the integrity, knowledge, 
imagination, skill, diversity and teamwork of Merck employees 
worldwide. We strive to reward their commitment and performance, 
and to respond to the needs of our employees and their families.
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We want each of our 95,000 Merck 
employees to feel like they own and are 
responsible for the business. So we 
are building on the robust values-based 
foundations of both Merck and Schering-
Plough to create a singular organizational 
culture that is characterized by candor 
and courage, and that is dedicated 
to rapid decision making and an intense 
customer focus. 
We consider diversity and inclusion 
an integral part of the culture we seek 
to build. Creating opportunities for all 
employees has always been more than a 
moral imperative for Merck. We believe 
that having a diverse, inclusive workforce 
is a strategic imperative that makes us 
a more innovative and agile company, 
attuned to the needs of our customers 
in the 140 countries in which we 
now operate. 
Successful integration requires that our 
employees have new and stronger 
capabilities. Our goal is to retain and 
develop talent at every level and in 
each area of the combined organization. 
Our ability to excel depends 
on the integrity, knowledge, 
imagination, skill, diversity and 
teamwork of our employees. 
To this end, we strive to create 
an environment of mutual 
respect, encouragement 
and teamwork.
This holds true even as the company goes 
through a period of workforce reductions. 
As part of the fi rst phase of the Merger 
Restructuring Program, by the end 
of 2012, the company expects to reduce 
our total workforce by approximately 
15 percent across all areas of the 
company worldwide. The company also 
plans to eliminate 2,500 vacant positions 
as part of the fi rst phase of this 
program. These reductions build on the 
restructuring programs that were 
underway in each company prior to the 
merger. Together they are reducing our 
cost structure, increasing effi ciency and 
enhancing our competitiveness without 
affecting our ability to deliver on our core 
mission of helping patients be well.
Our priority is to quickly create the 
right structure with the right people in 
the right jobs. This requires diffi cult 
decisions, and we are committed to 
making them in a responsible way, with 
respect, transparency and open, ongoing 
communication. We are providing 
opportunities for dialogue through which 
employees can ask questions and receive 
candid responses. We are honoring all 
contractual obligations to both legacy 
Merck and Schering-Plough employees, 
and providing fair severance packages, 
counselling and job search assistance. 
2010 HIGHLIGHT
365 Merck Days
Merck employees around the world 
are involved in volunteer efforts that 
improve their communities and 
enhance their neighbors’ well-being. In 
February 2010, we introduced 365 Merck 
Days to celebrate that giving spirit. A 
MerckVolunteers intranet site provides 
information on how employees can 
become involved in volunteer activities 
and showcases how colleagues in the 
company are making a difference by 
volunteering their personal time in their 
communities. Merck recognizes and 
rewards the volunteer efforts of our global 
employees, granting employees 20 hours 
per year of time during regular work 
hours to volunteer at eligible organizations. 
Employees who invest 40 hours of 
service each calendar year with an 
eligible organization can apply for a 
$500 contribution for the organization.
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ETHICS, COMPLIANCE AND TRANSPARENCY
OUR REPUTATION AND THE TRUST THAT 
HEALTH CARE PROVIDERS AND PATIENTS 
PLACE IN US DEPEND ON HOW WE 
CONDUCT OURSELVES AS A BUSINESS. 
Operating ethically, with integrity and with respect for human rights 
is critical to Merck’s success and to the well-being of the patients we 
serve. The importance of this behavior is underscored in the company’s 
code of conduct, Our Values and Standards.
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At Merck, behaving ethically and in 
compliance is the responsibility of 
everyone, every day, in everything we do. 
In 2009, we created a Global Compliance 
Organization and appointed Dr. Richard 
Bowles as Chief Compliance Offi cer (CCO), 
reporting directly to Merck’s Chairman 
and CEO. Through central leadership and 
management, the CCO acts as the steward 
for compliance across the organization, 
working in partnership with the business 
to ensure Merck achieves its business 
goals while meeting the letter and spirit 
of the complex regulatory framework 
in which we operate. The CCO sets and 
guides policy development, promotes 
and monitors compliance, and implements 
systems to identify, assess and act on 
potential risks to the company. 
Within the compliance organization, the 
Offi ce of Ethics serves as the foundation 
of Merck’s global business ethics 
programs around the world. It actively 
supports Merck’s commitment to high 
standards by facilitating behavior 
consistent with our code of conduct and by 
fostering a culture that promotes the 
prevention, detection and resolution of 
potential misconduct. Through it, we map 
out clear expectations for employees and 
hold them accountable for their behavior. 
Importantly, we are working to establish 
a culture where employees are willing to 
ask questions and where they feel safe 
to speak up. We have a number of employee 
resources available for raising questions 
or concerns regarding business practices, 
including the Offi ce of Ethics, the 
Ombudsman offi ce and a global Advice 
Line – a toll-free telephone service 
operated by a third-party vendor, available 
to all Merck employees seven days a 
week, 24 hours a day.
Our reputation, and the trust that health 
care providers and patients place in us, 
depend in large part on how we conduct 
ourselves. We believe the best way to 
address the concerns and questions about 
how we do business is to be more 
transparent about the way we operate. 
Since 2007, we have registered, at 
trial initiation, all clinical trials in 
patients (Phases I–V) that the company 
sponsors and conducts worldwide on 
www.ClinicalTrials.gov. We also disclose 
results from all registered clinical trials 
of marketed products – regardless of 
outcome – on www.ClinicalTrials.gov.
In October 2008, Merck started reporting 
grants over $500 provided by the 
company’s Global Human Health division 
to U.S. organizations in support of 
independent, accredited educational 
programs for health care professionals. 
In 2009, we expanded our public disclosure 
of our fi nancial support for third-party 
groups, including grants, charitable 
contributions and membership fees we 
make to patient organizations, medical 
scientifi c groups and professional 
societies in the United States, Canada, 
Europe, the Middle East and Africa. 
We also began disclosing payments to 
health care providers who speak on our 
behalf in the United States. Our intention 
is to eventually include payments to 
speakers outside the United States. In 2011, 
we plan to begin disclosing payments made 
to U.S.-licensed physicians who perform 
certain consulting services for Merck.
To improve access to information about 
Merck’s corporate political contributions 
in the United States, Merck also annually 
posts the company’s contributions 
categorized by state, candidate and 
amount. Merck also discloses any 
contributions to committees known as 
527 organizations. Beginning in 2009, 
we expanded this list to include corporate 
contributions in Australia and Canada, 
and we continued to disclose the portion 
of dues that major U.S.-based trade 
associations report to us as being used 
for advocacy and/or political activities 
where dues are greater than $50,000.
Merck is committed 
to maintaining the highest 
standards of ethics and 
integrity. We also remain 
committed to operating 
openly and have taken 
significant steps recently 
to improve transparency.
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ENVIRONMENT
WE ARE WORKING TO SUSTAIN AND CONTINUOUSLY 
IMPROVE OUR COMPLIANCE PROGRAMS AND 
ENVIRONMENTAL CONTROLS WHILE ENHANCING 
THE EFFICIENCY OF OUR USE OF ENERGY, 
WATER AND OTHER NATURAL RESOURCES.
We believe that an important part of our mission to improve human health is the 
protection of the environment. Merck’s vision is to have world-class environmental 
programs and performance, including taking actions to manage the risks 
and opportunities of climate change and water scarcity across our business. 
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We believe, as a health care company, 
that we have a role to play in under-
standing, identifying and responding to 
the potential health implications that 
may result from climate change and other 
environmental issues. 
Under a newly expanded corporate Global 
Safety and Environment organization 
and the guidance of an enhanced 
Environmental, Health and Safety 
policy, we are working to sustain and 
continuously improve our compliance 
programs and environmental controls 
while enhancing the effi ciency of our 
use of energy, water and other natural 
resources in our business. 
We have undertaken several initiatives 
to increase our energy effi ciency and also 
have begun to reduce our dependency 
on fossil fuels. In 2009, we added two 
major solar installations at our offi ces in 
New Jersey, both among the largest of 
their kind in a corporate setting. Together, 
they will avoid the production of more than 
2,500 tons of carbon dioxide emissions 
annually. And in 2010, we will begin to 
operate our fi rst wind turbines at one of 
our U.K. manufacturing facilities. The 
greening of our fl eet is also helping to 
reduce the environmental impact of our 
sales activities. Merck’s U.S. Fleet Services 
has changed its engine standards from 
6-cylinder to 4-cylinder and in the past 
three years the U.S. fl eet has been 
reduced by 5,500 vehicles. Globally, our 
fl eet also includes a signifi cant number 
of hybrid vehicles.
To reduce our use of water, we have a 
global water reduction program that 
requires all of our major facilities to 
document how much water is coming 
into the site, how it is used, how much is 
reused and where it is discharged. This 
process helps us identify water waste 
and opportunities for improvement. 
Cutting down our use of water is especially 
critical where water shortages are 
severe. For example, our manufacturing 
facility in Australia has focused on 
both employee culture and on water-
conserving practices to become the 
fi rst pharmaceutical company to achieve 
“5 Star Accreditation” under the 
Sydney Water Authority Every Drop 
Counts Program. 
Using engineering principles and 
innovative chemistry, we are reducing 
our use of raw materials, energy, and 
water in the manufacturing of our 
products. Merck scientists are applying 
their expertise in green chemistry 
principles to manage our expanded 
research activities and manufacturing 
processes in an environmentally 
responsible manner. By applying these 
principles in our process design, we 
have prevented the creation of many 
thousands of gallons of solvent waste. 
We are also exploring ways to recover 
and reuse solvents to reduce their 
environmental impacts both upstream 
and downstream of our fencelines. In 
2009, six of our plants – two in France, 
three in the Netherlands and one in the 
United States – used more regenerated 
than fresh solvents. 
We also are working to reduce the amount 
of packaging material and waste associated 
with our products. We are piloting a 
recycling program for our insulated vaccine 
shipping containers, which will recycle 
these containers and reduce the waste 
sent to landfi ll. In our Consumer Health 
Business, we are replacing PVC plastic 
with recyclable materials in the redesigned 
Dr. Scholl’s® packaging, which will 
eliminate an estimated 400,000 pounds 
of waste material each year. 
2010 HIGHLIGHT
Merck and Codexis, Inc.
In 2010, Merck and Codexis, Inc. were 
jointly awarded the annual Presidential 
Green Chemistry Challenge Award from 
the U.S. Environmental Protection Agency 
for the development of a novel biocatalytic 
method for the synthesis of sitagliptin.
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 2009 2008 2007 2006 2005
Economic indicators
Sales ($USM) [a] 27,428.3 23,850.3 24,197.7 22,636.0 22,011.9
Global tax expense as reported on income statement ($USM) [a] 2,267.6 1,999.4 95.3 1,787.6 2,732.6
Cash dividends paid per common share ($US) [a] [b] 1.52 1.52 1.52 1.52 1.52
Researching new medicines and vaccines to address unmet needs
Merck’s investment in R&D programs ($USB) [c] 5.8 4.8 4.9 4.8 3.8
Number of new products approved (number of products in 
pipeline and under regulatory review) [d]
1 (47) 1 (47) 2 (49) 5 (57) 2 (58)
Percentage of top 20 global burdens of illness addressed by 
our products and pipeline (as defi ned by WHO and excluding 
accidents, premature birth and self-infl icted injuries) [e]
50 50 60 N/R N/R
Improving access to medicines, vaccines and health care
Number of Merck products for which access prices are offered 
to least developed countries
6 6 6 2 2
Number of patients on Merck ARV therapy – all formulations, 
all products
372,362 [f] 653,867 763,118 701,391 N/D
Percentage of total patients on Merck ARVs estimated to be 
children taking pediatric formulations
16 17 15 19 N/D
Number of countries where Merck has committed to 
access prices for GARDASIL and ROTATEQ
72 72 72 N/R N/R
Number of new country registrations of GARDASIL and 
ROTATEQ globally (and cumulative to date)
10 (206) 18 (196) 72 (178) 105 (106) 1 (1)
Product donations ($USM) (% in the developing world) [g] 1,015 (70) [h] 766 (77) 766 (79) 768 (58) [i] 979 (45)
Millions of treatments approved through the MECTIZAN 
Donation Program (at 3 tablets per treatment)
209 174 128 118 114
Number of patients utilizing Merck’s Patient Assistance 
Program (total value of Merck medicines dispensed under 
Merck’s PAP [$USM]) [j]
331,890 (302) 250,285 (174) 350,000 (161.5) 540,240 (326) 730,000 (502)
Major PPPs to improve access to medicines, vaccines 
and/or health care [k]
11 11 13 12 10
Conducting ourselves ethically and transparently
Number of calls to the Merck AdviceLine and the 
Schering-Plough Integrity Action Line
392 151 149 77 80
Number of calls to the Merck Offi ce of Ethics/Ombudsman and 
Schering-Plough’s Compliance Offi ce
652 583 600 597 770
Number of warning letters or untitled letters from DDMAC or APLB 2 0 N/R N/R N/R
KEY PERFORMANCE INDICATORS
In 2009, we continued to measure our performance in each of our priority corporate responsibility areas against 
defi ned key performance indicators. As a result of the merger between Merck and Schering-Plough, the following list 
of key performance indicators represents those metrics that we can report on for the full year for the combined 
company, unless otherwise noted. We are working to harmonize the metrics of the two companies and plan to publish, 
by the end of 2010, a new set of short- and long-term targets. We will begin reporting on them in 2011 and 2012.
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 2009 2008 2007 2006 2005
Managing our environmental footprint
Environmental inspections 193 101 76 88 N/D
Notices of environmental violations/citations [l] 30 9 13 11 N/D
Environmental fi nes paid ($US) (number of fi nes) 8,000 (1) 1,579,600 [m] (7) 31,515 (6) 10,652 (3) 281,025 (4)
Total energy supply (million BTUs x 106) 26.1 12.8 15.2 15.5 17.5
Energy demand intensity (million BTU/sq ft) [n] 0.45 0.47 0.52 0.54 0.61
Total GHG emissions (as C02 eq) (million metric tons) [o] 2.14 1.18 1.29 1.29 1.36
Total water usage (billion gallons) 7.4 5.6 8.8 9.6 10.1
Nitrogen oxides (NOx) emissions (metric tons) 467 297 318 322 471
Sulfur oxides (SOx) emissions (metric tons) 96 50 58 67 84
Emissions of volatile organic compounds (VOCs) (metric tons) 1,103 353 401 [p] 427 411
Total waste generated (metric tons) 140,000 74,000 86,000 N/D N/D
Advocacy and outreach
Political contributions US$ [q]
United States $602,950 $597,775 $470,625 $611,975 $337,140
Australia $4,000 $5,050 $19,195 $20,292 $12,137
Canada $33,980 $30,695 $58,396 $45,765 $46,700
Valuing our employees
Number of employees (approximate) 100,000 55,200 59,800 60,000 61,000
% of Women on the Board 17 21 23 25 25
% of Women in executive roles (U.S.) 25 28 27 26 28
% of Under-represented ethnic groups on the Board 11 14 17 17 17
% of Under-represented ethnic groups in executive roles 13 11 11 12 12
Number of position eliminations through Merck’s 
restructuring program [r]
4,881 5,800 2,400 3,700 1,100
Overall turnover rate [s] 5.0 [t] 17.6 10.7 11.9 10.6
Safety inspections 140 75 41 65 N/D
Notices of safety violations/citations [l] 5 7 3 8 N/D
Safety fi nes paid (US$) (number of fi nes) 1,350 (1) 0 (0) 1,500 (1) 1,975 (2) 1,000 (2)
Recordable Injury Rate (RIR) [u] 0.92 1.10 1.12 1.11 1.21
20
KEY
N/A: Not applicable. N/D: No data. N/R: Not reported
[a]  Amounts for 2009 include the impact of the merger with Schering-Plough 
Corporation on November 3, 2009. Amounts for periods prior to November 3, 2009 
refl ect the results of Merck Sharp & Dohme Corp. (“Old Merck”), formerly known 
as Merck & Co., Inc.
[b]  Amount for 2009 refl ects dividends paid to common shareholders of Old Merck. 
In addition, approximately $144 million of dividends were paid subsequent 
to the merger with Schering-Plough, and $431 million was paid prior to the 
merger, relating to common stock and preferred stock dividends declared 
by Schering-Plough in 2009.
[c] Research activities and investments include all Merck divisions.
[d]  2009 data refl ect the company’s research pipeline as of February 12, 2010, and 
includes candidates in Phase II–III, excluding candidates in Phase I. Prior year 
data refl ects candidates in Phase I–III. (Source: 10K)
[e]  The decrease in 2008 is due mainly to the changing nature of the Global Burden of 
Disease as defi ned by WHO. Prior year data has been modifi ed to refl ect a correction 
identifi ed after publication of the previous report.
[f]  The decrease in the estimated number of patients on Merck ARV therapy in 2009 
is due in part to the elimination of a compliance factor of 1.28 used in previous years’ 
estimations. Additionally, the number of patients treated with generic ARVs has 
increased signifi cantly, especially in developing countries.
[g]  We value our product donations based on the U.S. wholesale acquisition cost. 
[h]  The number in 2009 refl ects the fi rst full year with ISENTRESS® (raltegravir) and 
ATRIPLA® (efavirenz 600 mg/emtricitabine 200 mg, tenofovir disoproxil fumarate 
300 mg) included in our ACHAP donations, more than doubling the value of ARVs 
donated to the program. Also, 2009 was the fi rst year in which donations were made 
through the GARDASIL Access Program.
[i]  The decrease in product donations is due in part to declining patient enrollment in 
our Corporate U.S. Patient Assistance Program, attributed in part to an increasing 
number of patients with prescription drug coverage, including through the Medicare 
Prescription Drug Program, which began on January 1, 2006. 
[j]  Totals include the Merck Patient Assistance Program, the U.S. Merck Vaccine 
Patient Assistance Program, the Schering-Plough Patient Assistance Program 
and the Merck/Schering-Plough Pharmaceuticals Patient Assistance Program and 
are based on the U.S. wholesale acquisition cost; the decrease in numbers is due in 
part to the increasing number of patients with prescription drug coverage, including 
the Medicare Prescription Drug Program.
[k]  Major is defi ned as with an investment by Merck of more than $500,000 per year 
and/or engagement with a national government. Therefore, in 2009 these included 
ACHAP, C-MAP, Diabetes Alliance, GARDASIL Access Program, MCAN, MDP, 
MMOP, MSD Wellcome Trust Hilleman Laboratories, MVN-A, Nicaraguan Rotavirus 
Vaccination Program, and the Measles Initiative.
[l]  Refl ects defi nitions of NOVs used by each company prior to the merger. A consistent 
defi nition will be used for reporting 2010 performance.
(m)  Refl ects a signifi cant environmental settlement ($1,575,000), paid in early 2008, 
associated with three spills that occurred in 2006.
[n]  The difference between demand energy and supply energy is losses in energy 
production at Merck facilities.
[o]  In accordance with US EPA Climate Leaders Protocol, GHG generation baseline data 
have been adjusted to remove facilities that have been sold.
[p]  Data unavailable for a site sold at the end of 2007.
[q]  Prior to the merger, Schering-Plough also had a policy of disclosing its 
U.S. corporate and political action committee contributions. These contributions 
were made in accordance with Schering-Plough Corporation’s guiding principles.
[r]  Position eliminations include separations and vacancy eliminations.
[s]  Overall turnover incorporates all types of turnover, including restructuring.
[t]  The decrease in the overall turnover rate in 2009 refl ects the exclusion of 
retirements and deaths in the number reported for voluntary turnover.
[u]  LTIR/RIR: calculated per OSHA methodology.
[v]  In 2008 a change was made to the defi nition of accidents to include only business-
related accidents. In 2009, we returned to the prior approach.
 2009 2008 2007 2006 2005
Valuing our employees (continued)
Lost-Time Incident Rate (LTIR) [u] 0.41 0.42 0.48 0.43 0.44
Fatalities 2 1 1 0 0
Accidents Per Million Miles (APMM) 10.97 7.03 [v] 9.64 9.92 10.40
Supply chain management
Spending on diverse suppliers in the U.S. (%) 10 14 12 8 5
Philanthropy
Merck’s philanthropic contributions (total cash and product) ($USM) 1,083 821 828 826 1,039
Cash contributions ($USM) 68 55 62 58 60
KEY PERFORMANCE INDICATORS
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PRINTING INFORMATION
Environmental benefits based on 4,384 lbs. 
of 100% post-consumer recycled paper, 
actual environmental savings versus standard 
paper are as follows:
» 42 trees saved
» 17,878 gallons of waste water avoided
» 29,811,200 BTUs of energy not consumed
  Access to Medicine Index (ATMI) – Ranked Merck No. 2 in the 2010 Access to Medicine Index, which assesses and 
ranks pharmaceutical companies on various criteria around global access to medicines. Merck ranked No. 1 in 
the category of product donations and philanthropy. (2010)
  Dow Jones Sustainability Indexes – For the second year in a row, Merck has been placed on the Dow Jones 
Sustainability North America Index, which is based on a thorough analysis of corporate economic, environmental, 
and social performance. The North America Index captures the leading 20 percent in terms of sustainability out 
of the largest 600 North America companies. (2010)
  FTSE4Good Index – Merck is an FTSE4Good constituent member. The FTSE4Good Index Series has been designed to 
measure the performance of companies that meet globally recognized corporate responsibility standards. (2010)
  Corporate Responsibility Offi cer Magazine – Ranked Merck No. 17 on the 11th Annual 100 Best Corporate Citizens List. 
The list rates companies on their performance in seven key areas: environment, climate change, human rights, 
philanthropy, employee relations, fi nancial and governance. (2010)
  DiversityInc – Ranked Merck No. 13 in its annual list of the “Top 50 Companies for Diversity,” marking the company’s 
eighth consecutive appearance on the list. (2010)
  Human Rights Campaign Corporate Equality Index – Merck scored 100 percent on the Corporate Equality Index, 
which rates companies on a scale of 0 to 100 percent based on standards set by the Human Rights Campaign. (2010)
  U.S. Environmental Protection Agency – Recognized Merck with the 2010 Energy Star Sustained Excellence Award 
for continued efforts to protect the environment through energy effi ciency.  Merck, an Energy Star partner since 
2004, has been recognized by the EPA for fi ve consecutive years – twice as Partner of the Year and now for the 
third time for Sustained Excellence.  (2010)
  Merck and Codexis, Inc. have jointly been awarded the annual Presidential Green Chemistry Challenge Award from 
the U.S. Environmental Protection Agency (EPA) for the development of a novel biocatalytic method for the synthesis of 
sitagliptin. The Presidential Green Chemistry Challenge Awards are presented annually to recognize new technologies 
that help prevent pollution by reducing or eliminating hazardous waste in industrial production.
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CONTACT US:
Send us your comments and feedback 
about this Review at:
www.merck.com/cr/contacts
GEN-2010-WS-10056-PU
OR WRITE TO US:
Merck & Co., Inc.
Offi ce of Corporate Responsibility
WS 2A-55
One Merck Drive
PO Box 100
Whitehouse Station, NJ 08889 
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